Anna Maria Fulghesu, M. D. , Mario Ciampelli, M. D. , Giuseppe Muzj, M

Slides:

Advertisements

Similar presentations

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary.

Advertisements

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin.

A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio Anna Maria Fulghesu, M.D., Mario Ciampelli,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome Silvia Ajossa, M.D., Stefano Guerriero, M.D.,

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome Elisabeth Lerchbaum,

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic.

The spectrum of androgen excess disorders

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot.

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.

Differential lipopolysaccharide (LPS)-stimulated TNFα release from mononuclear cells (MNC) of normal weight vs. obese women with polycystic ovary syndrome.

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study A. Nasr Reproductive BioMedicine Online

A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome Dorte Glintborg, M.D., Ph.D.,

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis Shiqin Zhu, M.D., Bingqian Zhang, M.D.,

Cardiovascular risk in normal weight, eumenorrheic, nonhirsute daughters of patients with polycystic ovary syndrome: a pilot study Cesare Battaglia,

Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis Francesca Moro, M.D., Clara De Simone,

Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity Jean-Patrice Baillargeon, M.D.,

Low-dose hormone therapy and carbohydrate metabolism

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome Macarena Alpañés, M.D., Manuel.

Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women.

Increased secretion of amylin in women with polycystic ovary syndrome

Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic.

Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations Daniela Romualdi, M.D., Ph.D., Gian Franco.

Massimo Tartagni, M. D. , Luca Maria Schonauer, M. D

Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome Carlos Moran, M.D.,

Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women.

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Naloxone decreases insulin secretion in hyperinsulinemic postmenopausal women and may positively affect hormone replacement therapy Francesco Cucinelli,

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Serum resistin levels in women with polycystic ovary syndrome

Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome Derek A Haas, M.D., Bruce.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin Elsy Velázquez M, M.D.,

Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D

Dijana Hadžiomerović, M. D. , Bernhard Rabenbauer, M. D

Paolo Moghetti, M.D. Fertility and Sterility

Are patients with idiopathic hirsutism (IH) insulin resistant

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Increased total and phosphorylated glycogen synthase kinase-3 (GSK-3) in the adipocytes of patients with the polycystic ovary syndrome (PCOS) W.Y. Chang,

Operative transvaginal hydrolaparoscopy for treatment of polycystic ovary syndrome: a new minimally invasive surgery Hervé Fernandez, M.D., Jean-Dominique.

Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome Mesut Ozkaya, Assistant Professor, Erman Cakal, Specialist, Yusuf.

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Increased risk of depressive disorders in women with polycystic ovary syndrome Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,

Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Basak Yildirim, M.D., Nuran Sabir,

Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3 Wendy Chang, M.D.,

Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M

Enrico Carmina, M.D., Rogerio A Lobo, M.D. Fertility and Sterility

Presentation transcript:

N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome Anna Maria Fulghesu, M.D., Mario Ciampelli, M.D., Giuseppe Muzj, M.D., Chiara Belosi, M.D., Luigi Selvaggi, M.D., Gian Franco Ayala, M.D., Antonio Lanzone, M.D. Fertility and Sterility Volume 77, Issue 6, Pages 1128-1135 (June 2002) DOI: 10.1016/S0015-0282(02)03133-3

FIGURE 1 Metabolic parameters in the normoinsulinemic women with PCOS (14 patients) before and after NAC treatment. Data are expressed as mean ± SD. A, AUC of insulin expressed as μIU/mL × 240 minutes. B, AUC of C-peptide expressed as ng/mL × 240 minutes. C, Total body glucose utilization (M) expressed as mg/kg/min. ∗P<.05 Before (pre) vs. after (post) NAC treatment. Fulghesu. NAC and insulin in polycystic ovary syndrome. Fertil Steril 2002. Fertility and Sterility 2002 77, 1128-1135DOI: (10.1016/S0015-0282(02)03133-3)

FIGURE 2 Metabolic parameters in the hyperinsulinemic women with PCOS (17 patients) before and after NAC treatment. Data are expressed as mean ± SD. A, AUC of insulin expressed as μIU/mL × 240 minutes. B, AUC of C-peptide expressed as ng/mL × 240 minutes. C, Total body glucose utilization (M) expressed as mg/kg/min. ∗P<.05 Before (pre) vs. after (post) NAC treatment. Fulghesu. NAC and insulin in polycystic ovary syndrome. Fertil Steril 2002. Fertility and Sterility 2002 77, 1128-1135DOI: (10.1016/S0015-0282(02)03133-3)

FIGURE 3 Metabolic parameters in the hyperinsulinemic women with PCOS (six patients) before and after placebo treatment. Data are expressed as mean ± SD. A, AUC of insulin expressed as μIU/mL × 240 minutes. B, AUC of C-peptide expressed as ng/mL 240 minutes. C, Total body glucose utilization (M) expressed as mg/kg/min. Fulghesu. NAC and insulin in polycystic ovary syndrome. Fertil Steril 2002. Fertility and Sterility 2002 77, 1128-1135DOI: (10.1016/S0015-0282(02)03133-3)